The Multiple Myeloma Channel on VJHemOnc is an independent medical education platform, supported with funding from BMS (Gold) and Legend Biotech (Bronze). Supporters have no influence on the production of content. The levels of sponsorship listed are reflective of the amount of funding given.
IMS 2021 | UNIVERSAL: initial results of ALLO-715 in myeloma
Parameswaran Hari, MBBS, MD, Medical College of Wisconsin, Milwaukee, WI, outlines the findings of the Phase I UNIVERSAL trial (NCT04093596) of ALLO-715, a B-cell maturation antigen (BCMA)-targeted chimeric antigen receptor (CAR) T-cell therapy for patients with relapsed/refractory multiple myeloma. Initial lymphodepletion involved fludarabine, cyclophosphamide and ALLO-647 (FCA), with the medial time for starting therapy being 5 days after enrollment. No reports of graft-versus-host disease (GvHD), or neurotoxicity were observed, and 40% of patients achieved a very good partial response (VGPR). Dr Hari additionally discusses potential addition of γ-secretase inhibitors to improve CAR T-cell efficacy. This interview took place during the 2nd Immune Effector Cell Therapy in MM Workshop in Boston, MA.
